Blar i forfatter "Blix, Egil Støre"

Viser treff 1-8 av 8

    • Advanced flow cytometry to study signaling pathways and predict outcome in B cell malignancies 

      Blix, Egil Støre (Doctoral thesis; Doktorgradsavhandling, 2015-01-16)

    • Content of endothelial progenitor cells in autologous stem cellgrafts predict survival after transplantation for multiplemyeloma 

      Blix, Egil Støre; Kildal, Anders Benjamin; Bertelsen, Eirin Listau; Waage, Anders; Myklebust, June; Kolstad, Arne; Husebekk, Anne (Journal article; Tidsskriftartikkel; Peer reviewed, 2015-02-14)
      Multiple myeloma (MM) is considered an incurable B cell malignancy, although many patients can benefit from high-dose therapy with autologous stem cell transplantation (ASCT) as a first-line treatment. In nonHodgkin lymphoma (NHL), ASCT is usually performed after relapse with curative intent. Disease progression is often associated with increased angiogenesis, in which endothelial progenitor cells ...

    • Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer 

      Yndestad, Synnøve; Engebrethsen, Christina; Herencia-Ropero, A.; Nikolaienko, Oleksii; Vintermyr, Olav Karsten; Lillestøl, Reidun Kristine; Minsaas, Laura; Leirvaag, Beryl; Iversen, Gjertrud Titlestad; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Aase, Hildegunn Siv; Aas, Turid; Gudlaugsson, Einar; Llop-Guevara, Alba; Serra, Violeta; Janssen, Emiel; Lønning, Per Eystein; Knappskog, Stian; Eikesdal, Hans Petter (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-12-01)
      Purpose - Homologous recombination deficiency (HRD) is highly prevalent in triple-negative breast cancer (TNBC) and associated with response to PARP inhibition (PARPi). Here, we studied the prevalence of HRD in non-TNBC to assess the potential for PARPi in a wider group of patients with breast cancer.<p> <p>Methods - HRD status was established using targeted gene panel sequencing (360 genes) and ...

    • Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway 

      Helland, Åslaug; Russnes, Hege Elisabeth Giercksky; Fagereng, Gro Live; Al-Shibli, Khalid Ibrahim; Andersson, Yvonne; Berg, Thomas; Bjørge, Line; Blix, Egil Støre; Bjerkehagen, Bodil; Brabrand, Sigmund; CAMERON, MARTE; Dalhaug, Astrid; Dietzel, Dalia; Dønnem, Tom; Enerly, Espen; Flobak, Åsmund; Fluge, Sverre; Gilje, Bjørnar; Gjertsen, Bjørn Tore; Grønberg, Bjørn Henning; Grønås, Kari; Guren, Tormod Kyrre; Hamre, Hanne Mari; Haug, Åse; Heinrich, Daniel; Hjortland, Geir Olav; Hovig, Eivind; Hovland, Randi; Iversen, Ann-Charlotte; Janssen, Emiel; Kyte, Jon A; Gythfeldt, Hedda; Lothe, Ragnhild Adelheid; Lund, Jo-Åsmund; Meza, Leonardo Zepeda; Munthe-Kaas, Monica Cheng; Nguyen, Olav Toai Duc; Niehusmann, Pitt; Nilsen, Hilde; Puco, Katarina; Ree, Anne Hansen; Riste, Tonje Bøyum; Semb, Karin; Steinskog, Eli Sihn Samdal; Stensvold, Andreas; Suhrke, Pål; Tennøe, Øyvind Krohn; Tjønnfjord, Geir Erland; Vassbotn, Liv Jorunn; Aas, Eline; Aasebø, Kristine Øverås; Tasken, Kjetil; Smeland, Sigbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-05-14)
      Background: Matching treatment based on tumour molecular characteristics has revolutionized the treatment of some cancers and has given hope to many patients. Although personalized cancer care is an old concept, renewed attention has arisen due to recent advancements in cancer diagnostics including access to high-throughput sequencing of tumour tissue. Targeted therapies interfering with cancer ...

    • Low Z-4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen 

      Helland, Thomas; Naume, Bjørn; Hustad, Steinar; Bifulco, Ersilia; Kvaløy, Jan Terje; Sætersdal, Anna Barbro; Synnestvedt, Marit; Lende, Tone Hoel; Gilje, Bjørnar; Mjaaland, Ingvil; Weyde, Kjetil; Blix, Egil Støre; Wiedswang, Gro; Borgen, Elin; Hertz, Daniel Louis; Janssen, Emiel; Mellgren, Gunnar; Søiland, Håvard (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-12-14)
      Abstract Low steady‐state levels of active tamoxifen metabolites have been associated with inferior treatment outcomes. In this retrospective analysis of 406 estrogen receptor‐positive breast cancer (BC) patients receiving adjuvant tamoxifen as initial treatment, we have associated our previously reported thresholds for the two active metabolites, Z‐endoxifen and Z‐4‐hydroxy‐tamoxifen (Z‐4OHtam), ...

    • Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 

      Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Journal article; Tidsskriftartikkel; Peer reviewed, 2020-11-23)
      <p><i>Background - </i>The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic triple negative breast cancer (TNBC) wild type for BRCA1/2, we hypothesized that PARPi may be effective in primary TNBCs without previous chemotherapy exposure. < ...

    • Phospho-spesific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma 

      Blix, Egil Støre; Irish, Jonathan M.; Husebekk, Anne; Delabie, Jan; Forfang, Lise; Tierens, Anne; Myklebust, June; Kolstad, Arne (Journal article; Tidsskriftartikkel; Peer reviewed, 2012)
      Knowledge about signaling pathways in malignant cells may provide prognostic and diagnostic information in addition to identify potential molecular targets for therapy. B-cell receptor (BCR) and co-receptor CD40 signaling is essential for normal B cells, and there is increasing evidence that signaling via BCR and CD40 plays an important role in the pathogenesis of B-cell lymphoma. The aim of this ...

    • Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial 

      Mecinaj, Albulena; Gulati, Geeta; Heck, Siri Lagethon; Holte, Espen; Fagerland, Morten Wang; Larsen, Alf Inge; Blix, Egil Støre; Geisler, Jürgen; Wethal, Torgeir; Omland, Torbjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2021-09-27)
      Background - Recent advances in the treatment algorithms of early breast cancer have markedly improved overall survival. However, anthracycline- and trastuzumab-associated cardiotoxicity may lead to dose-reduction or halt in potentially life-saving adjuvant cancer therapy. Early initiated neurohormonal blockade may prevent or attenuate the cardiotoxicity-induced reduction in cardiac function, but ...